What is the recommended treatment for dyshidrotic eczema in a child?

Treatment of Dyshidrotic Dermatitis in Children

For dyshidrotic dermatitis in children, start with low to medium potency topical corticosteroids applied twice daily to affected areas, combined with liberal emollient use, and consider topical calcineurin inhibitors (tacrolimus 0.03% or pimecrolimus 1%) for maintenance therapy or sensitive areas. 1

First-Line Treatment Approach

Topical Corticosteroids

• Use low to medium potency topical corticosteroids (TCS) as the primary treatment for acute flares in children, applied twice daily 1
• Infants and young children require less potent TCS than adults due to increased risk of adrenal suppression 1
• Duration of exposure to potent TCS should be limited, especially on sensitive areas (face, neck, skin folds) to avoid skin atrophy 1
• Medium potency TCS can be used for longer periods on trunk and extremities in chronic cases 1

Essential Adjunctive Therapy

• Apply bland, thick emollients liberally and regularly as basic therapy—this has both short- and long-term steroid-sparing effects 1, 2
• Bathe with water alone or nonsoap cleansers 2-3 times weekly, followed immediately by emollient application 3
• Regular moisturizer use improves skin barrier function, which is particularly important in dyshidrotic eczema 1

Second-Line Options

Topical Calcineurin Inhibitors (TCIs)

• Tacrolimus 0.03% ointment or pimecrolimus 1% cream are steroid-sparing alternatives approved for children aged 2 years and above 1
• Particularly useful for maintenance therapy and sensitive skin areas where corticosteroid use should be limited 1, 4
• In a randomized trial, tacrolimus 0.1% showed more than 50% reduction in dyshidrotic area and severity index after 2 weeks, comparable to mometasone furoate 5
• TCIs can be used for proactive therapy with twice-weekly application to previously affected areas to prevent relapses in moderate to severe cases 1

Wet-Wrap Therapy

• Consider wet-wrap therapy with TCS for moderate to very severe cases failing conventional topical treatment 1
• This is an effective short-term second-line treatment, recommended for 3-7 days with possible extension to 14 days maximum 1
• Wet dressings promote trans-epidermal penetration of TCS and serve as barriers against scratching 1

Treatment Algorithm by Severity

Mild Disease

• Reactive therapy with low to medium potency TCS 1
• Alternative: pimecrolimus cream for reactive therapy 1
• Liberal emollient use as basic therapy 1

Moderate Disease

• Proactive and reactive therapy with low to medium potency TCS 1
• Consider TCIs (pimecrolimus or tacrolimus) for proactive/reactive therapy 1
• Continue aggressive emollient regimen 1

Severe/Refractory Disease

• Proactive and reactive therapy with low to high potency TCS combined with tacrolimus 1
• Wet-wrap therapy should be considered before systemic therapies 1
• For cases unresponsive to topical measures, phototherapy may be considered in children 12 years and older (not recommended for younger children due to unclear long-term safety) 1

Important Clinical Considerations

Infection Management

• Deterioration in previously stable eczema may indicate secondary bacterial infection 2
• Long-term topical antibiotics are NOT recommended due to resistance and sensitization risk 1
• If bacterial infection is clinically evident, use systemic antibiotics rather than topical 1
• Topical anti-inflammatory therapy with TCS or TCIs can reduce Staphylococcus aureus colonization by improving skin barrier function 1

Common Pitfalls to Avoid

• Do not use topical antihistamines—insufficient evidence for efficacy and may increase contact dermatitis risk 1
• Avoid long-term oral corticosteroids due to unfavorable risk-benefit profile and rebound flares upon discontinuation 1
• Do not prescribe inadequate quantities of emollients—these should be used liberally and frequently 2
• Ensure proper education on application technique, as this is essential for treatment success 2

Special Phototherapy Considerations

• UVA1 phototherapy and PUVA have shown efficacy in adult studies of dyshidrotic eczema 6, 7
• However, phototherapy is not recommended for children younger than 12 years as long-term safety remains unclear 1
• For adolescents 12 years and older with severe refractory disease, narrowband UVB may be considered 1

Emerging Evidence

• Newer biologics like dupilumab are approved for moderate to severe atopic dermatitis in children 6 years and above, though specific data for isolated dyshidrotic eczema is limited 1
• One case report showed successful treatment of severe dyshidrotic eczema with tralokinumab in an adult, suggesting potential future options 8

Patient and Family Education

• Adequate time for explanation and demonstration of application techniques is essential 2
• Counsel families on trigger avoidance, including irritants and excessive sweating 1
• Educate about the chronic, relapsing nature of the condition to set realistic expectations 9
• Written information should reinforce verbal instructions 2